ClinicalTrials.Veeva

Menu

Diagnostic Consistency of GLIM and PG-SGA for Malnutrition in Pancreatic Cancer

H

Hebei Medical University

Status

Completed

Conditions

Pancreatic Neoplasms

Treatments

Diagnostic Test: Global Leadership Initiative on Malnutrition (GLIM) Criteria Assessment
Diagnostic Test: Patient-Generated Subjective Global Assessment (PG-SGA)

Study type

Interventional

Funder types

Other

Identifiers

NCT07057895
2022S00558

Details and patient eligibility

About

This study aimed to evaluate the diagnostic consistency between the Global Leadership Initiative on Malnutrition (GLIM) criteria and the Patient-Generated Subjective Global Assessment (PG-SGA) for identifying malnutrition in patients with pancreatic malignant tumors. The goal is to determine if the GLIM criteria, a newer and more streamlined tool, shows substantial agreement with the well-established PG-SGA, thereby supporting its use in this high-risk clinical population.

Full description

Pancreatic cancer is a highly aggressive malignancy often associated with severe nutritional decline. While the Nutritional Risk Screening 2002 (NRS 2002) is used for initial screening and the Patient-Generated Subjective Global Assessment (PG-SGA) is a recognized standard for detailed nutritional assessment, the PG-SGA can be time-consuming. The Global Leadership Initiative on Malnutrition (GLIM) criteria were developed to provide a globally harmonized, two-step framework for diagnosing malnutrition. This prospective observational study was designed to compare the performance of GLIM criteria against the PG-SGA in patients with pancreatic cancer. Patients admitted to the hospital were screened with NRS 2002. Those at nutritional risk (NRS 2002 ≥ 3) were then comprehensively assessed using both PG-SGA and GLIM criteria. The study hypothesis is that the GLIM criteria and PG-SGA will demonstrate good consistency in diagnosing malnutrition in this population, validating GLIM as a practical and reliable assessment tool in clinical settings.

Enrollment

108 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Histopathologically confirmed pancreatic malignant tumor.
  • Age ≥ 18 years.
  • Clear cognition and ability to communicate verbally.
  • Nutritional Risk Screening 2002 (NRS 2002) score ≥ 3.
  • Provision of written informed consent to participate.

Exclusion criteria

  • Presence of severe cardiac, hepatic, or renal comorbidities.
  • Bedridden status precluding weight measurement.
  • Contraindications to bioelectrical impedance analysis (e.g., implanted electronic devices, amputation).
  • Concurrent diagnosis of other malignant tumors, particularly of the digestive system.
  • Inability to cooperate with questionnaire completion or assessments.

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

None (Open label)

108 participants in 1 patient group

Nutritional Assessment Cohort
Experimental group
Description:
A single cohort of patients with pancreatic cancer and nutritional risk (NRS 2002 ≥ 3) who underwent comprehensive nutritional assessment using both the GLIM criteria and the PG-SGA to evaluate the diagnostic consistency between the two tools. All participants in this arm receive all listed diagnostic procedures.
Treatment:
Diagnostic Test: Patient-Generated Subjective Global Assessment (PG-SGA)
Diagnostic Test: Global Leadership Initiative on Malnutrition (GLIM) Criteria Assessment

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems